Clinical trial registry record

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 9, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07216131
Last registry update
January 9, 2026
Status
Completed
Phase
Phase 1
Sponsor
AstraZeneca
Enrollment
14
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
14
Population
ALL · 18 Years to 55 Years
Duration
2025-11-10 to 2025-12-30
Intervention
AZD0780; Metformin
Comparator
Not reported
Outcomes measured
Area under concentration time curve from time 0 to infinity (AUCinf) — Days 1 to 3 and Days 8 to 10; Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) — Days 1 to 3 and Days 8 to…; Maximum observed drug concentration (Cmax) — Days 1 to 3 and Days 8 to 10; Number of participants with Adverse Events (AEs) — Day 1 until Follow-up visit or early discontinuation (Up to Day 18); Apparent total body clearance (CL/F) — Days 1 to 3 and Days 8 to 10; Apparent volume of distribution based on the terminal phase (Vz/F) — Days 1 to 3 and Days 8 to 10; Terminal elimination half life (t½λz) — Days 1 to 3 and Days 8 to 10; Time to reach maximum observed concentration (tmax) — Days 1 to 3 and Days 8 to 10; Renal clearance (CLR) — Days 1 to 3 and Days 8 to 10; Amount of unchanged drug excreted into urine (Ae) — Days 1 to 3 and Days 8 to 10; Percentage of dose excreted unchanged in urine (fe) — Days 1 to 3 and Days 8 to 10
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →Export JSON